Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

304 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
How should multiple myeloma research change in a patient-oriented world? Findings and lessons from the pan-Canadian myeloma priority setting partnership.
Bridges S, Fowler S, McLaughlin L, Robichaud M, Ridgway B, Reece D, Song K, Dalrymple L, Sully R, Nason S, Rowland S, MacDonald T, Paine W, Gulliver A, Reiman A. Bridges S, et al. Among authors: reece d. Res Involv Engagem. 2023 Jul 29;9(1):60. doi: 10.1186/s40900-023-00476-9. Res Involv Engagem. 2023. PMID: 37516883 Free PMC article.
Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database.
McCurdy A, Louzada M, Venner CP, Visram A, Masih-Khan E, Kardjadj M, Jimenez-Zepeda VH, LeBlanc R, Sebag M, Song K, White D, Mian H, Stakiw J, Reiman A, Aslam M, Kotb R, Gul E, Reece D. McCurdy A, et al. Among authors: reece d. EJHaem. 2022 Aug 31;3(4):1252-1261. doi: 10.1002/jha2.559. eCollection 2022 Nov. EJHaem. 2022. PMID: 36467802 Free PMC article.
Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis.
McCurdy A, Mian H, LeBlanc R, Jimenez-Zepeda VH, Su J, Masih-Khan E, Visram A, Louzada M, Song K, White D, Sebag M, Stakiw J, Reiman A, Aslam M, Bergstrom D, Kotb R, Kaedbey R, Gul E, Reece D, Venner CP. McCurdy A, et al. Among authors: reece d. Blood Cancer J. 2023 Aug 28;13(1):129. doi: 10.1038/s41408-023-00888-6. Blood Cancer J. 2023. PMID: 37635183 Free PMC article. No abstract available.
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Dimopoulos MA, et al. Among authors: reece d. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9. Lancet Haematol. 2022. PMID: 35550060 Clinical Trial.
Understanding real-world treatment patterns and clinical outcomes in AL amyloidosis patients diagnosed in Canada: A population-based cohort study.
Jimenez-Zepeda VH, Reece D, Rigo R, Gogna P, Kong S, Hu XY, Chapani P, Cheung WY, Brenner DR, Plante R, Shi K, Husain A, Tankala D, Boyne DJ. Jimenez-Zepeda VH, et al. Among authors: reece d. EJHaem. 2022 Sep 5;3(4):1262-1269. doi: 10.1002/jha2.562. eCollection 2022 Nov. EJHaem. 2022. PMID: 36467790 Free PMC article.
Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial.
Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Ahmadi T, Qin X, Garvin Mayo W, Gai X, Carey J, Carson R, Moreau P. Dimopoulos MA, et al. Among authors: reece d. J Clin Oncol. 2023 Mar 10;41(8):1590-1599. doi: 10.1200/JCO.22.00940. Epub 2023 Jan 4. J Clin Oncol. 2023. PMID: 36599114 Free PMC article. Clinical Trial.
Validation of an administrative coding algorithm for the identification of individuals with amyloid light chain amyloidosis using administrative data.
Jimenez-Zepeda VH, Reece D, Rigo R, Gogna P, Kong S, Hu XY, Chapani P, Cheung WY, Brenner DR, Plante R, Shi K, Husain A, Ammann E, Tankala D, Boyne DJ. Jimenez-Zepeda VH, et al. Among authors: reece d. Leuk Lymphoma. 2023 Jan;64(1):256-258. doi: 10.1080/10428194.2022.2136967. Epub 2022 Nov 21. Leuk Lymphoma. 2023. PMID: 36409003 No abstract available.
304 results